Lokalna primena timolola u lečenju površnih infantilnih hemangioma kod veoma rano prevremeno rođene dece
Sažetak
Uvod. Infantilni hemangiomi (IH) se javljaju 3 do 4 puta češće kod prevremeno rođene dece nego kod one rođene u terminu. Ipak, podaci o efikasnosti i sigurnosti lokalne terapije IH kod prevremeno rođene dece, naročito one sa veoma niskom gestacijom (manje od 33 nedelje gestacije) su veoma oskudni. Prikaz bolesnika. U radu je prikazano 5 devojčica rođenih sa veoma niskom gestacijom koje su lečene lokalnom primenom 0,5% gela timolol maleata zbog površnih kutanih IH. Kod četvoro dece, timololom je bio tretiran po jedan IH, a kod jednog deteta su tretirana dva IH. Od ukupno šest tretiranih IH, jedan je bio lociran na licu, četiri na trupu i jedan na nozi. Tokom trajanja terapije (od 6 do 13 meseci), redovno je praćeno napredovanje involucije IH i eventualna pojava neželjenih efekata. Dobar terapijski efekat je postignut kod sve dece, a neželjeni efekti, koji bi se mogli povezati sa lokalnom primenom timolola, nisu zapaženi. Zaključak. Lokalna primena timolola predstavlja efikasnu i bezbednu terapijsku opciju za lečenje površnih kutanih infantilnih hemangioma kod dece rođene sa veoma niskom gestacijom. O terapiji se mora detaljno prodiskutovati sa roditeljima i treba sačiniti individualizovani terapijski plan za svako dete, kako bi se povećale šanse za terapijski uspeh, a izbegli neželjeni efekti.
Reference
Goelz R, Poets CF. Incidence and treatment of infantile hae-mangioma in preterm infants. Arch Dis Child Fetal Neonatal Ed 2015; 100: 85–91.
Garzon MC, Drolet BA, Baselga E, Chamlin SL, Haggstrom AN, Horii K, et al. Comparison of Infantile Hemangiomas in Pre-term and Term Infants: A Prospective Study. Arch Dermatol 2008; 144(9): 1231‒2.
Munden A, Butschek R, Tom WL, Marshall JS, Poeltler DM, Krohne SE, et al. Prospective study of infantile hemangiomas: Incidence, clinical characteristics, and association with placen-tal anomalies. Br J Dermatol 2014; 170(4): 907‒13.
Janmohamed SR, de Waard-van der Spek FB, Madern GC, de Laat PC, Hop WC, Oranje AP. Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS). Clin Exp Dermatol 2011;36(7):715-23
Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358(24): 2649–51.
Guo S, Ni N. Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Arch Ophthalmol 2010; 128(2): 255–6.
Vivas-Colmenares GV, Bernabeu-Wittel J, Alonso-Arroyo V, Matute de Cardenas JA, Fernandez-Pineda I. Effectiveness of Propranolol in the Treatment of Infantile Hemangioma Be-yond the Proliferation Phase. Pediatric Dermatology 2015; 32(3): 348‒52.
Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128(2): e259‒66.
Zaher H, Rasheed H, Hegazy RA, Hegazy RA, Abdelhalim DM, Gawdat HI. Oral propranolol: an effective, safe treatment for infantile hemangiomas. Eur J Dermatol 2011; 21(4): 558‒63.
Zvulunov A, McCuaig C, Frieden IJ, Mancini AJ, Puttgen KB, Dohil M et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol 2011; 28(2): 94‒8.
Wu HW, Liu C, Wang X, Zhang L, Yuan W, Zheng JW, et al. Topical Application of 0.5% Timolol Maleate Hydrogel for the Treatment of Superficial Infantile Hemangioma. Front Oncol 2017; 7: 137.
Danarti R, Ariwibowo L, Radiono S, Budiyanto A. Topical Tim-olol Maleate 0.5% for Infantile Hemangioma: Its Effective-ness Compared to Ultrapotent Topical Corticosteroids – A Single-Center Experience of 278 Cases. Dermatology 2016; 232(2): 566‒71.
Moehrle M, Leaute-Labreze C, Schmidt V, Röcken M, Poets CF, Goelz R. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol 2013; 30(2): 245–9.
Chan H, McKay C, Adams S, Wargon O. RCT of Timolol Male-ate Gel for Superficial Infantile Hemangiomas in 5- to 24-Week-Olds. Pediatrics 2013; 131(6): e1739‒47.
Yu L, Li S, Su B, Liu Z, Fang J, Zhu L, et al. Treatment of su-perficial infantile hemangiomas with timolol: Evaluation of short-term efficacy and safety in infants. Exp Ther Med 2013; 6(2): 388‒90.
Luu M, Frieden IJ. Haemangioma: clinical course, complica-tions and management. Br J Dermatol 2013; 169(1): 20‒30.
Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for in-fantile hemangioma: report of a consensus conference. Pediat-rics 2013; 131(1): 128–40.
Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plast Reconstr Surg 2012; 130(3): 619–24.
Bauland CG, Luning TH, Smit JM, Zeebregts CJ, Spauwen PH. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg 2011; 127(4): 1643–8.
Theiler M, Hoffman WY, Frieden IJ. Breast Hypoplasia as a Complication of an Untreated Infantile Hemangioma. Pediatr Dermatol 2016; 33(2): e129‒30.
Zaher H, Rasheed H, Esmat S, Hegazy RA, Gawdat HI, Hegazy RA, et al. Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial. Eur J Dermatol 2013; 23(5): 646–52.
Gan LQ, Ni SL, Tan Q, Wang H. A Retrospective Study of Propranolol Therapy in 109 Infants with Infantile Hemangio-ma. Pediatric Dermatol 2013; 30(2): 270‒2.
Schupp CJ, Kleber JB, Günther P, Holland-Cunz S. Propranolol Therapy in 55 Infants with Infantile Hemangioma: Dosage, Duration, Adverse Effects, and Outcome. Pediatr Dermatol 2011; 28(6): 640‒4.
Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N. Severe Hypoglycemia During Successful Treatment of Diffuse Hemangiomatosis with Propranolol. Pediatr Dermatol 2010; 27(2): 195‒6.
Langley A, Pope E. Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas. Br J Dermatol 2015; 172(1): 13–23.
Gonzalez-Llorente N, del Olmo-Benito I, Munoz-Ollero N, Descalzo MA, Garcia-Doval I, Torrelo A. Study of Cognitive Function in Children Treated with Propranolol for Infantile Hemangioma. Pediatr Dermatol 2017; 34(5): 554‒8.
Semkova K, Marina S, Kazandjieva J. Topical treatment of infan-tile hemangiomas – where are we now? Serb J Dermatol Vene-reol 2011; 3(4): 145‒52.
Ng MSY, Tay YK, Ng SS, Foong AYW, Koh MJ. Comparison of Two Formulations of Topical Timolol for the Treatment of Infantile Hemangiomas. Pediatr Dermatol 2017; 34(4): 492‒3.
Frommelt P, Juern A, Siegel D, Holland K, Seefeldt M, Yu J, et al. Adverse Events in Young and Preterm Infants Receiving Top-ical Timolol for Infantile Hemangioma. Pediatr Dermatol 2016; 33(4): 405‒14.